Testing a new version of Dupixent in healthy men
Treatments studied
This study tests a new version of the medicine Dupixent (called GLR1044) to see if it works the same as the original. It is for healthy men to check safety and how the body handles the medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be a man aged 18 to 55 years old
- Have a body mass index (BMI) between 19 and 26, and weigh between 55 and 85 kg
- Be in good health with no major medical conditions
- Agree to use reliable birth control during the study and for 6 months after
- Not have used certain medicines or participated in other drug trials recently
- Be able to follow study rules and attend all visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new experimental drug called PG-033 in healthy adults. It helps doctors find out if the drug is safe and how your body processes it at different dose levels.
This trial tests a single dose of a new medicine called PG-033 in healthy adults. It checks how the drug moves through the body and how food affects it, to find the safest starting dose for future studies.
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
This trial tests whether an experimental medication, QL2108, works as well as a standard treatment (Dupixent) for moderate-to-severe atopic dermatitis (eczema). It may help reduce the severity of eczema symptoms and improve quality of life.
This Phase 4 study looks at how dupilumab works in people with moderate-to-severe atopic dermatitis (eczema), and whether the mechanism differs across ethnic backgrounds. If you’re eligible, it may help doctors understand who benefits most from dupilumab.
Hear when a new Biosimilarity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.